A clinical trial to investigate how the DailyColors(TM) dietary supplement affects markers of health in older adults
| ISRCTN | ISRCTN10734674 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN10734674 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Protocol serial number | 124914 |
| Sponsor | University of Exeter |
| Funder | DailyColors(TM) Health Inc. |
- Submission date
- 18/11/2024
- Registration date
- 20/11/2024
- Last edited
- 20/11/2024
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Other
Plain English summary of protocol
Background and study aims
The Mediterranean diet is known to be linked to better health, including brain health. This is thought to be due to high levels of polyphenols in these foods, particularly in fruit and vegetables. Taking supplements of key nutrients has been suggested as a way of supporting healthy ageing and protecting brain health since many adults do not eat enough of these foods in their normal diet. This study investigates the impact of a new supplement, DailyColors™ which combines extracts from polyphenol-rich foods to see if there is an impact on key indicators of health in people at risk of poor health in older age.
Who can participate?
Adults aged 50 years and over with a Body Mass Index of 25 kg/m2 and above, who are participants in the PROTECT-UK ageing cohort online platform
What does the study involve?
All participants will receive tablets in the post containing either a placebo, low dose or high dose of DailyColors™. They will take two tablets twice a day for 60 days. They will also complete online assessments of cognition and health on the PROTECT-UK platform. A sub-group of 45 participants will be invited to attend two clinics (at the start and after 60 days) to provide a blood sample and complete physiological measures (height, weight and blood pressure).
What are the possible benefits and risks of participating?
Possible benefits include any potential benefit from the supplement although these are not known. Possible risks are low but may include an adverse reaction to the supplement, or discomfort following blood sampling for the sub-group.
Where is the study run from?
The University of Exeter (UK)
When is the study starting and how long is it expected to run for?
July 2023 to January 2024
Who is funding the study?
DailyColors™ Health Inc.
Who is the main contact?
Prof. Anne Corbett, A.M.J.Corbett@exeter.ac.uk
Contact information
Public, Scientific, Principal investigator
Dept of Health & Community Sciences
University of Exeter
Exeter
EX1 2LU
United Kingdom
| Phone | +44 (0)1392 661000 |
|---|---|
| a.m.j.corbett@exeter.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | 60-day three-arm exploratory mechanistic placebo-controlled double-blind online exploratory mechanistic randomized controlled trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Impact of the DailyColorsTM phytonutrient supplement on health markers in older adults: an exploratory mechanistic clinical trial |
| Study objectives | The DailyColors(TM) phytonutrient supplement will confer indications of benefit to cognition and physiological markers of health, and will elicit impacts on inflammatory pathways as a mechanism of benefit |
| Ethics approval(s) |
Approved 11/09/2023, University of Exeter Public Health & Sports Science REC (University of Exeter Medical School, Exeter, EX1 2LU, United Kingdom; +44 (0)1392 726621; shs-ethics-admin@exeter.ac.uk), ref: 2929219 |
| Health condition(s) or problem(s) studied | Adults aged 50 years and above with a BMI of 25 kg/m2 or above |
| Intervention | Minimisation randomisation using a validated randomised software module embedded in the PROTECT platform. Participants will be randomised into three treatment groups: 1. DailyColors (TM) phytonutrient dietary supplement High Dose (2000 mg/day) every day for 60 days 2. DailyColors (TM) dietary supplement Low Dose (750 mg/day) every day for 60 days 3. Placebo (inert packing ingredients) every day for 60 days The DailyColors(TM) supplement is a proprietary blend of freeze-dried powders and extracts from foodstuffs found in the Mediterranean diet. Active ingredients were packed into microcrystalline cellulose capsules containing additional inert packing ingredients of Natural Rice Concentrate (NuFlow) and Natural Rice Extract (MuMag) in quantities to ensure the correct dose. |
| Intervention type | Supplement |
| Primary outcome measure(s) |
Cognition as measured by the FLAME computerised cognitive test system, as described below: |
| Key secondary outcome measure(s) |
Full cohort: |
| Completion date | 24/01/2024 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Adult |
| Lower age limit | 50 Years |
| Upper age limit | 100 Years |
| Sex | All |
| Target sample size at registration | 150 |
| Total final enrolment | 150 |
| Key inclusion criteria | 1. Aged 50 years or above 2. BMI >25 kg/m2 3. Living within 2 hours travel from Exeter 4. Already a participant in the PROTECT-UK study 5. Access to a tablet or computer with an internet connection 6. Good understanding of the English Language, sufficient to participate |
| Key exclusion criteria | 1. Already taking part in another active interventional clinical trial 2. Vegan diet 3. Drinking more than five cups of coffee or tea per day 4. Regular consumption of anti-inflammatory medications 5. Use of dietary supplements rich in polyphenols (concentrate/freeze-dried powder of cherry, blueberry, pomegranate or cacao) 6. Current prescription of atorvastatin, simvastatin, calcium channel blocker (amlodipine, felodipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine, verapamil), warfarin, clopidogrel, ticagrelor, ciclosporin, sirolimus, tacrolimus and entocort due to contraindications of high intake of grapefruit 7. Diagnosis of dementia |
| Date of first enrolment | 19/09/2023 |
| Date of final enrolment | 02/11/2023 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Exeter
EX1 2LT
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan summary | Available on request |
| IPD sharing plan | The datasets generated during and/or analysed during the current study will be available on request from the PROTECT Research Group at protect.data@exeter.ac.uk |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
19/11/2024: Study's existence confirmed by the University of Exeter Public Health & Sports Science REC.